PLGA nanoparticles, 200nm 

PLGA nanoparticles, 200nm, are biodegradable tumor-targeting nanocarriers that can serve as drug delivery enhancers and multidrug resistance inhibitors. PLGA nanoparticles, 200nm, passively enriched through the EPR effect and actively targeted via ligand-mediated endocytosis, can encapsulate various antitumor active molecules. PLGA nanoparticles, 200nm can specifically recognize multiple types of tumor cells and improve cellular uptake, cytotoxicity and antiproliferative effects after modification with ligands such as transferrin, folic acid, and RGD. PLGA nanoparticles, 200nm can encapsulate various therapeutic drugs and can be surface modified to achieve targeting, imaging, and prolonged circulation time, making them suitable for cancer-related research^[1][2][3].

PLGA nanoparticles, 200nm loaded with Dexamethasone (HY-14648) completely inhibit the proliferation of vascular smooth muscle cells^[2].
PLGA nanoparticles, 200nm can deliver various active substances including p53 plasmids, Curcumin (HY-N0005), cysteine protease inhibitors, Camptothecin (HY-16560), Doxorubicin (HY-15142A), Paclitaxel (HY-B0015), Cisplatin (HY-17394), and Rapamycin (HY-10219), enhance drug accumulation in multiple tumor and smooth muscle cells, and prolong the duration of action^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CC(C)C(OCC(OC)=O)=O.[x].[y]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Bala I, et al. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21(5):387-422.  [Content Brief]